MOLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Molecular Partners AG (MOLN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company shows weak financial performance, with significant revenue and net income declines. Despite some bullish technical indicators, the lack of clear positive catalysts, recent analyst downgrades, and absence of strong trading signals suggest a cautious approach. Holding the stock or waiting for further developments, such as the upcoming financial report or pipeline readouts, is recommended.
The technical indicators show mixed signals. The MACD is slightly positive at 0.022, indicating weak bullish momentum, while the RSI is neutral at 53.724. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 4.801, with resistance at 5.053 and support at 4.549. However, these indicators alone do not provide a strong buy signal.
The company is attending multiple healthcare conferences in early March 2026, which could provide visibility and potential updates on its pipeline. The DARPin platform and focus on oncology could address unmet medical needs, as noted by H.C. Wainwright's buy rating.
Additionally, there are no significant insider or hedge fund trading trends, and no recent congress trading data.
In Q3 2025, the company reported a 100% YoY revenue decline (revenue dropped to 0), a net income decline of -27.85% YoY to -$11.836M, and an EPS drop of -32.65% YoY to -$0.33. Gross margin also dropped to 0, reflecting poor financial health.
Analyst sentiment is mixed. H.C. Wainwright initiated coverage with a Buy rating and a $13 price target, citing the potential of the DARPin platform. However, JPMorgan recently lowered its price target to $3.75 and maintained a Neutral rating, citing concerns over the lack of pipeline readouts in 2026.
